Raymond James Financial Services Advisors Inc. Sells 2,389 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Raymond James Financial Services Advisors Inc. lessened its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 50.1% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,378 shares of the biopharmaceutical company’s stock after selling 2,389 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Alnylam Pharmaceuticals were worth $452,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Meiji Yasuda Asset Management Co Ltd. increased its stake in Alnylam Pharmaceuticals by 4.3% during the 1st quarter. Meiji Yasuda Asset Management Co Ltd. now owns 1,220 shares of the biopharmaceutical company’s stock worth $244,000 after acquiring an additional 50 shares during the period. Captrust Financial Advisors increased its stake in Alnylam Pharmaceuticals by 4.3% during the 2nd quarter. Captrust Financial Advisors now owns 1,285 shares of the biopharmaceutical company’s stock worth $187,000 after acquiring an additional 53 shares during the period. Souders Financial Advisors increased its stake in Alnylam Pharmaceuticals by 2.6% during the 1st quarter. Souders Financial Advisors now owns 2,236 shares of the biopharmaceutical company’s stock worth $448,000 after acquiring an additional 57 shares during the period. Greenleaf Trust increased its stake in Alnylam Pharmaceuticals by 2.3% during the 1st quarter. Greenleaf Trust now owns 2,760 shares of the biopharmaceutical company’s stock worth $553,000 after acquiring an additional 61 shares during the period. Finally, First Trust Direct Indexing L.P. increased its stake in Alnylam Pharmaceuticals by 3.7% during the 2nd quarter. First Trust Direct Indexing L.P. now owns 2,371 shares of the biopharmaceutical company’s stock worth $450,000 after acquiring an additional 84 shares during the period. Institutional investors own 93.98% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Needham & Company LLC decreased their price target on Alnylam Pharmaceuticals from $240.00 to $200.00 and set a “buy” rating on the stock in a research note on Monday, October 9th. Raymond James started coverage on Alnylam Pharmaceuticals in a research report on Thursday, September 28th. They set an “outperform” rating and a $208.00 price objective on the stock. HC Wainwright reduced their price objective on Alnylam Pharmaceuticals from $405.00 to $395.00 and set a “buy” rating on the stock in a research report on Wednesday, October 11th. Oppenheimer lowered Alnylam Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Wednesday, October 11th. Finally, Royal Bank of Canada reduced their price objective on Alnylam Pharmaceuticals from $270.00 to $235.00 in a research report on Wednesday, October 11th. Seven analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $232.84.

Alnylam Pharmaceuticals Stock Performance

ALNY stock opened at $157.00 on Thursday. The stock’s 50 day simple moving average is $178.16 and its 200 day simple moving average is $189.26. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $148.10 and a fifty-two week high of $242.97. The company has a market cap of $19.63 billion, a P/E ratio of -18.23 and a beta of 0.48.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($2.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.72) by ($0.49). The company had revenue of $318.75 million during the quarter, compared to analyst estimates of $331.73 million. Equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -6.65 earnings per share for the current year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 4,166 shares of the business’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $183.89, for a total transaction of $766,085.74. Following the completion of the sale, the chief marketing officer now directly owns 4,345 shares of the company’s stock, valued at approximately $799,002.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 4,166 shares of the business’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $183.89, for a total transaction of $766,085.74. Following the completion of the sale, the chief marketing officer now directly owns 4,345 shares of the company’s stock, valued at approximately $799,002.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Jeffrey V. Poulton sold 3,460 shares of the business’s stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $185.85, for a total value of $643,041.00. Following the sale, the chief financial officer now directly owns 15,873 shares of the company’s stock, valued at $2,949,997.05. The disclosure for this sale can be found here. In the last three months, insiders have sold 15,144 shares of company stock valued at $2,806,347. 1.40% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.